Close Menu

CPT codes

The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.

In a letter to CMS, AMP made a case for crosswalking existing CPT codes for BRCA1/2 testing to codes that more accurately reflect the work required to analyze these genes.

The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.

Since last year the AMA has issued 23 PLA codes for firms that want to better track use of their tests, but the effect of the codes on improving reimbursement remains to be seen.

The panel's decisions could change the codes diagnostic companies use to bill payors for these tests, which could affect revenue.

The new code is used for tests conducted by next-generation sequencing that include BRCA1, BRCA2, and 12 other genes even if they are part of multi-gene panels.

The coding requirements will be a particularly complicated aspect of implementing the new law which aims to move diagnostic pricing to a market-based system.

Medicare Administrative Contractors didn't price codes describing whole-genome or exome sequencing, or cancer panels gauging 51 or more genes.

NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services has released its preliminary clinical laboratory fee schedule (CLFS) deter

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has issued draft local coverage determinations stipulating reimbursement criteria for three multi-marker molecular diagnostics: Assurex Health's pharmacogenetic test for refractory depression, MDxHealth's ConfirmMDx epigenetic prostate cance

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.